|
**Overview**: **SMAM-Spinal Muscular Atrophy Mutation Detection Panel****Introduction**: The Spinal Muscular Atrophy Mutation Detection Panel is a diagnostic tool designed to detect SMA mutations using whole blood samples. In India, SMA type 1 is the leading genetic cause of infant mortality, with >95 percent cases due to homozygous SMN1 exon 7/8 deletion; early diagnosis enables nusinersen or gene therapy in select centers. High morbidity from under-testing in rural/low-SES infants with hypotonia or respiratory failure, limited genetic labs, delayed diagnosis leading to rapid progression or death. Per pediatrics/genetics practices aligned with ICMR and Indian Society of Human Genetics guidelines, the test employs PCR for SMN1 exon 7/8 deletion, SMN2 copy number, and mutation status over 1-2 days with high accuracy, valuable for confirmatory diagnosis and prognosis (SMN2 copies correlate with severity). This diagnostic falls under genetic screening and targets infants with floppy infant syndrome or family history, addressing accurate detection to guide supportive care or advanced therapy. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling early intervention and reducing SMA mortality. Its whole blood-based approach ensures reliable deletion/copy number analysis.**Other Names**: SMA Mut Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology/cytogenetics, compliant with 2025 standards.**Historical Milestone**: SMN1 deletion testing standard; in India, expanding in pediatric neurology.**Purpose**: The test assesses 4 parameters including SMN1 Exon 7 Deletion to guide SMA mutation screening, detect deletions/copy number, inform prognosis/therapy.**Test Parameters**: 1. SMN1 Exon 7 Deletion, 2. SMN1 Exon 8 Deletion, 3. SMN2 Copy Number, 4. Mutation Status.**Pretest Condition**: No fasting required; patients should have hypotonia or regression.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve DNA integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for PCR).**Medical History**: Patients should provide details on motor delay, respiratory issues.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected SMA including mortality, benefits of early detection, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using PCR by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low DNA yield can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Homozygous SMN1 deletion confirms SMA; SMN2 copies predict severity, necessitating specialist input.**Specialist Consultation**: Pediatric neurologists or geneticists should be consulted for management.**Additional Supporting Tests**: Muscle biopsy, EMG for confirmation.**Test Limitations**: Detects common deletions; comprehensive approach required.**References**: Indian Journal of Pediatrics 2024, Genetic Studies India 2023. |
